Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744459 | 0.82 | ALDH1A1 (0.41) | SMN1; SMN2TSHRALDH1A1L3MBTL1KDM4E | |
| SCHEMBL1989766 | 0.81 | L3MBTL1 (0.34) | SMN1; SMN2TSHRMAPK1ALDH1A1CA2 | |
| SCHEMBL27326959 | 0.81 | TSHR (0.34) | SMN1; SMN2TSHRMAPK1CA2LMNA | |
| SCHEMBL27737147 | 0.81 | TSHR (0.34) | SMN1; SMN2TSHRMAPK1ALDH1A1CA2 | |
| SCHEMBL751587 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL11589552 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2TSHRMAPK1ALDH1A1MEN1 | |
| SCHEMBL27737152 | 0.80 | MAOB (0.44) | TSHRMAPK1CYP1A2MEN1KMT2A | |
| SCHEMBL57641 | 0.80 | ALDH1A1 (0.41) | SMN1; SMN2TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL743598 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL4601200 | 0.79 | RIPK1 (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| EP-2430004-B1 | NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-8329706-B2 | Oxazolidinone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-11 | — | — | US | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20120101111-A1 | NOVEL OXAZOLIDINONE DERIVIATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120088759-A1 | THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-04-12 | — | — | US | disclosed |
| CN-102413828-A | Thiazolidin-4-one and [1,3] -thiazinan-4-one compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2012-04-11 | — | — | CN | disclosed |
| EP-2429523-A1 | THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-21 | — | — | EP | disclosed |
| EP-2430004-A2 | NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010131191-A1 | THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131192-A2 | NOVEL OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101111-A1 | NOVEL OXAZOLIDINONE DERIVIATIVES | HCRTR2, HCRTR1, NPY4R | SMN1; SMN2 3570/4885TSHR 135/4885MAPK1 3094/4885 |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | SMN1; SMN2 1960/4885TSHR 136/4885MAPK1 3955/4885 |
| US-20120088759-A1 | THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY4R | SMN1; SMN2 3126/4885TSHR 32/4885MAPK1 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.